Surge of Over 40%! Privatization Ignites FRONTAGE Stock Price; Tigermed Plans to Divest Control, Reports Net Loss of 270 Million in First Three Quarters

LongbridgeAII'm LongbridgeAI, I can summarize articles.

On November 10, FRONTAGE (01521.HK) resumed trading with a significant surge, finally closing at HK$2.125 per share, up 42.62%, with a latest market capitalization of HK$4.332 billion.

In terms of news, on the evening of November 9, Tigermed (300347.SZ; 03347.HK) announced that to further focus on its core clinical CRO (Contract Research Organization) business and deepen its presence in the Chinese market, the company intends to participate in the privatization of its subsidiary FRONTAGE through its wholly-owned subsidiary, Hong Kong Tigermed Technology Co., Ltd. (hereinafter referred to as "Hong Kong Tigermed"), and to divest FRONTAGE's overseas laboratory business through a spin-off transaction.

Upon completion of the transaction, Tigermed will no longer hold shares in FRONTAGE, retaining only its business operations within China.

The other side of the asset divestiture is the current pressure on Tigermed's performance. The third-quarter report for 2026 shows that in the first three quarters of 2026, the company achieved revenue of RMB 5.792 billion, a year-on-year increase of 15.23%, but the net profit attributable to shareholders was a loss of RMB 272 million, turning from profit to loss compared to the same period last year.

Public information shows that Tigermed was co-founded by Cao Xiaochun and Ye Xiaoping and listed on the Shenzhen Stock Exchange in 2012. As a leader in the CRO industry, Tigermed achieved rapid expansion through simultaneous investment and M&A activities. However, this business model is highly susceptible to performance volatility, and the company's recent decline in performance has been dragged down by its investment segment.

Privatization Followed by Spin-off

The "mystery" behind FRONTAGE's trading suspension since October 22 has been revealed.

The announcement indicates that this transaction consists of two parts: privatization and a spin-off. Hong Kong Tigermed, US drug development services giant Charles River Laboratories International, Inc. (hereinafter referred to as "CRL", CRL.US), Li Song, and his related trusts jointly established SanRex. SanRex will serve as the acquisition entity to privatize FRONTAGE through a scheme of arrangement. Upon completion of the privatization, FRONTAGE will become a wholly-owned subsidiary of SanRex. The privatization price is HK$2.37 per share, representing a premium of approximately 107.9% over FRONTAGE's closing price of HK$1.14 per share on October 16.

In the spin-off transaction, FRONTAGE's existing business is divided into target business and non-target business. The target business includes FRONTAGE and its subsidiaries' bioanalysis and drug metabolism and pharmacokinetics (DMPK) businesses, including laboratory science operations at two locations in Pennsylvania, USA, central laboratory and diagnostic services, bioanalysis services (including large and small molecules), biologic testing services, biomarker services, and DMPK businesses.

CRL intends to acquire the target business at an initial transaction price of USD 470 million. Entities related to Li Song will acquire the non-target business outside China at an initial price of USD 84.4 million, while Tigermed will retain the non-target business within China at an initial transaction price of USD 205.5 million. Additionally, the transaction includes a performance bonus capped at USD 75 million.

Prior to this transaction, Tigermed held a total of 64.48% of FRONTAGE's shares. Upon completion, the company will no longer hold shares in FRONTAGE, retaining only the non-target business within China. The company expects that the profit generated from this transaction will account for more than 50% of the audited net profit of the most recent fiscal year.

Regarding the rationale for the sale, Tigermed stated in the announcement that FRONTAGE's main business and assets are located outside China, involving different operating costs and overseas management requirements compared to the company's core clinical CRO business. Divestiture will allow the company to focus on its core clinical CRO business and deepen its roots in the Chinese market. Ye Xiaoping, Chairman of Tigermed, described this move as "an important decision for Tigermed to focus on and execute its long-term strategic plan."

Previous announcements show that Tigermed acquired control of FRONTAGE in 2014; initiated the spin-off of FRONTAGE for listing on the Hong Kong Stock Exchange in early 2018; and FRONTAGE listed on the Hong Kong Stock Exchange in May 2019.

In terms of performance, FRONTAGE's revenue in 2025 and the first half of 2026 was USD 257 million and USD 148 million, respectively, with net profits of USD 6.762 million and USD 6.788 million, respectively.

It is worth noting that FRONTAGE announced on the evening of October 21 that it would suspend trading starting October 22. Before the suspension, on October 19 and October 20, the company's stock rose sharply by 15.35% and 13.31%, respectively. Prior to this, the company's performance in the secondary market had been lukewarm, with its stock price hovering around HK$1 for a long period.

Decline in Investment Income, Turning from Profit to Loss in First Three Quarters

Public information shows that Tigermed was co-founded by Cao Xiaochun and Ye Xiaoping. Both are professionals in the field; Cao Xiaochun has over 35 years of experience in drug R&D and clinical research, while Ye Xiaoping worked in the medical registration departments of Xi'an Janssen, Bristol-Myers Squibb, and Roche for more than 10 years.

Around the year 2000, there were still significant gaps in the domestic CRO industry. Cao Xiaochun and Ye Xiaoping, two senior pharmaceutical professionals, hit it off and decided to start a business together. In the early stages, Cao Xiaochun accepted Ye Xiaoping's startup capital of RMB 100,000 to establish Hangzhou Tigermed Consulting Co., Ltd. In 2004, Ye Xiaoping resigned from Roche, and the two formally established Tigermed.

Under their joint efforts, Tigermed quickly emerged in the industry. In 2012, Tigermed listed on the Shenzhen Stock Exchange, and in 2020, it listed on the Hong Kong Stock Exchange, achieving a dual "A+H" listing. On November 10, Tigermed's A-shares fell 0.04%, closing at RMB 51.25 per share, with a latest market capitalization of RMB 43.83 billion; its H-shares rose 0.26%, closing at HK$38.94 per share, with a latest market capitalization of HK$33.3 billion.

Financial report information shows that currently, Ye Xiaoping and Cao Xiaochun are the actual controllers of Tigermed, holding 20.58% and 5.96% of the company's shares, respectively.

Under the leadership of Ye Xiaoping and Cao Xiaochun, Tigermed has been quite active in capital operations. On one hand, the company has continuously expanded its business landscape through acquisitions. In July 2025, Tigermed acquired Micron, a Japanese CRO company specializing in image analysis. Previously, the company also acquired several CRO or pharmaceutical R&D enterprises, including Europe's Marti Farm, Beiyi Renzhi, South Korea's DreamCIS, and Canada's BRI.

On the other hand, Tigermed began to vigorously layout investments in the pharmaceutical industry around 2015, flourishing in primary and secondary market investments, pharmaceutical funds, and more.

On June 3 of this year, Tigermed announced that it would invest RMB 200 million through Hangzhou Tigermed Equity Investment Partnership (Limited Partnership) in Shanghai Sansheng Pharmaceutical Private Equity Investment Partnership (Limited Partnership). Other partners in this private equity fund include 3SBio and Shanghai State-owned Capital Venture Biopharmaceutical Private Equity Investment Fund Partnership (Limited Partnership).

Financial reports show that as of the end of the first half of 2026, Tigermed's other non-current financial assets amounted to RMB 9.613 billion, including RMB 707 million in listed company shares, RMB 4.413 billion in pharmaceutical funds, and RMB 4.369 billion in equity investments in unlisted companies.

As of the end of the third quarter of 2026, the company's other non-current financial assets and long-term equity investments totaled RMB 14.323 billion, accounting for more than half of its total assets.

However, this business model is highly susceptible to performance volatility, and Tigermed's decline in performance in the first three quarters was dragged down by its investment segment. The third-quarter report shows that in the first three quarters of 2026, the company's revenue was RMB 5.792 billion, a year-on-year increase of 15.23%; net profit attributable to shareholders was -RMB 272 million, compared to RMB 1.02 billion in the same period last year, turning from profit to loss year-on-year. During the reporting period, the company's gain/loss from changes in fair value was -RMB 597 million, compared to RMB 323 million in the same period last year, and investment income was only RMB 29.3285 million, compared to RMB 440 million in the same period last year.

Read Original

Source: QQ News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.